P&T COMMUNITY
 
MediMedia Managed Markets
Our
Other
Journal
Managed Care magazine
P&T Community, The Online Resource for P&T Decision Makers
Login / Register
Join Us  Facebook  Twitter  Linked In

 

News Categories

 

 

 

FDA Approves First Recombinant Coagulation Factor IX (Rixubis) for Hemophilia B

Approval provides alternative option to prevent bleeding episodes (June 27)

The FDA has approved Rixubis (Coagulation Factor IX [Recombinant], Baxter Healthcare) for use in patients with hemophilia B who are 16 years of age and older. Rixubis is indicated for the control and prevention of bleeding episodes, perioperative management, and routine use to prevent or reduce the frequency of bleeding episodes (prophylaxis).

An inherited blood clotting disorder mainly affecting males, hemophilia B is caused by mutations in the factor IX gene and leads to deficiency of factor IX. Hemophilia B affects approximately 3,300 people in the U.S. Individuals with hemophilia B can experience potentially serious bleeding, mainly into the joints, which can be destroyed by such bleeding.

“As the first recombinant coagulation factor IX indicated specifically for routine prophylaxis to prevent bleeding, Rixubis becomes a new weapon in our arsenal to protect hemophilia B patients,” said Karen Midthun, MD, director of the FDA’s Center for Biologics Evaluation and Research. “This approval provides patients and physicians with an alternative treatment option to prevent or reduce the frequency of bleeding episodes.”

Rixubis is a purified protein produced by recombinant DNA technology. It does not contain human or animal proteins. It is supplied in single-use vials of freeze-dried powder and is administered by intravenous injection after reconstitution with sterile water for injection. When used for the routine prevention of bleeding episodes, it is administered twice weekly.

The efficacy of Rixubis was evaluated in a multicenter study in which 73 male patients between 12 and 65 years of age received Rixubis for routine prophylaxis or as needed in response to symptoms of bleeding. Overall, patients in the prophylaxis study had a 75% lower annual bleeding rate compared with that of patients who had received on-demand treatment. An additional study in a pediatric population is currently ongoing.

Although serious side effects, including anaphylaxis, can occur, the most common side effects observed in patients in clinical studies were dysgeusia, pain in an extremity, and atypical blood test results.

Source: FDA; June 27, 2013.

More stories